Los puntos clave no están disponibles para este artículo en este momento.
SOX2-OT may serve as a promising noninvasive plasma-based tumor biomarker for LSCC.
Teng et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: